ATRA
NASDAQ · Biotechnology
Atara Biotherapeutics Inc
$7.93
-0.30 (-3.65%)
Open$8.37
Previous Close$8.23
Day High$8.41
Day Low$7.70
52W High$19.15
52W Low$3.92
Volume—
Avg Volume23.8K
Market Cap79.90M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-11.2% upside
Current
$7.93
$7.93
Target
$7.04
$7.04
$5.84
$7.04 avg
$9.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 96.41M | 77.84M | 4.60M |
| Net Income | 26.09M | 18.96M | -132,709 |
| Profit Margin | 27.1% | 25.7% | -2.9% |
| EBITDA | 30.32M | 23.26M | -214,542 |
| Free Cash Flow | — | — | -85,981 |
| Rev Growth | +23.9% | +23.9% | -8.7% |
| Debt/Equity | 0.04 | 0.04 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |